Intraocular Lymphomas

Dear colleagues,

Intraocular lymphomas comprise vitreoretinal and uveal lymphomas. Vitreoretinal lymphoma (VRL) usually affects both eyes and is associated with poor life expectancy because of CNS involvement. Many patients are misdiagnosed as having chronic uveitis. Vitrectomies are required for diagnosis which need a specialised work-up in expert laboratories. There is no consensus on the standard of care for VRL patients. Most receive ocular radiotherapy or a variety of intravitreal drugs. Systemic therapy may be administered even without evidence of CNS disease. Whether any of these treatments improve survival remains controversial. Prospects for improving outcomes have recently been enhanced by advances in ocular imaging (e.g., wide-angle photography, optical coherence tomography and autofluorescence imaging), molecular pathology (e.g., MYD88 mutational analysis, next generation sequencing and metagenomic deep sequencing), and novel therapies (e.g., therapeutic vitrectomy and intravitreal injections of melphalan and rituximab). Survival of some VRL patients has been prolonged by combining high-dose chemotherapy with immunomodulators (e.g., lenalidomide), BCL-2 and MYD88 inhibitors as well as kinase inhibitors (e.g., Phosphatidil-inositol 3δ-kinase and Bruton’s tyrosine kinase inhibitors). Uveal lymphoma, in contrast, is a low-grade lymphoma, which has a good prognosis and responds to low-dose radiotherapy, although there may be better treatments. This Special Issue highlights recent advances and scope for further research.

Prof. Bertil E. Damato
Prof. Sarah E. Coupland
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• intraocular lymphomas
• vitreoretinal lymphoma
• uveal lymphoma
• intraocular chemotherapy
• ocular radiotherapy
• CNS lymphoma